Agarose Bead Technologies (ABT) has completed the extension of its agarose resin manufacturing facility in Burgos, Spain.
The expansion of the facility was completed in June 2024, and is now fully operational.
The 1000m2 addition means that ABT is now one of Europe's largest manufacturers of agarose resins.
Through this expansion, ABT can now better meet the global demand for agarose resins in the pharmaceutical and bioprocessing industries.
ABT's Burgos facility now houses two cleanroom facilities, while also having more storage space for larger volumes of product.
In a year, the company is now able to produce approximately 100,000L of resins per year.
Agarose Bead Technologies supports businesses throughout the pharmaceutical industry, including those involved in the development of novel cell & gene therapies and vaccines.
Because a majority of these advanced therapies require complex purification, the demand for high-quality agarose resins has seen an uptick.
The CEO of Agarose Bead Technologies, Carolina Egea, commented: “Our investment in expanding the Burgos facility is a direct response to the increasing global demand for high-quality agarose resins. This enhanced capacity will enable us to meet the evolving needs of the pharmaceutical industry, improve supply chain reliability, and reinforce our role as a trusted partner in the development of life-saving therapies.”
“The new facility will incorporate energy-efficient systems and waste-reduction strategies.”
